Browsing Pharmacy and Pharmaceutical Sciences by Sponsor "Trinity Foundation"
Now showing items 1-1 of 1
-
Neratinib-resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4
(2017)Background: Neratinib is in Phase 3 clinical trials but, unfortunately, the development of resistance is inevitable. Here, we investigated the effects of acquired neratinib resistance on cellular phenotype and the ...